Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, has announced that the first patient has been dosed in its ongoing phase 2a clinical trial evaluating ONP-002, the company’s lead candidate for the treatment of concussion and mild traumatic brain injury (mTBI). The milestone was achieved at Mackay Hospital in Australia — the first site to be activated in the trial — within days of site activation on 31 March 2026.
Concussion, aka, mild traumatic brain injury, represents the most prominent neurological conditions without an FDA-approved pharmacological treatment. According to the CDC, an estimated 1.7 to 3.8 million people in the US experience traumatic brain injuries annually, with sports and recreational activities among the leading causes.
Globally, an estimated 69 million individuals sustain traumatic brain injuries each year. Despite this scale, no pharmacological treatments have been approved — leaving patients, military personnel, athletes, and families with few effective options beyond rest and symptom management.
If approved by the FDA, ONP-002 would be the first and only pharmacological standard of care for a global concussion market projected to reach over $9 billion by 2030.
The commencement of patient dosing follows the receipt of Human Research Ethics Committee (HREC) approval in Australia and the activation of Mackay Hospital as the first clinical site. The rapid presentation of an eligible patient immediately upon site activation underscores the breadth and urgency of unmet clinical need in this population.
Two additional Australian sites — Alfred Hospital (Melbourne) and Royal Adelaide Hospital (Adelaide) — are progressing through site governance approvals, with activation expected in the second quarter of 2026.
ONP-002 is a first-in-class intranasal novel neurosteroid designed to address the underlying biology of brain injury — reducing neuroinflammation, oxidative stress, and cerebral edema — rather than simply managing symptoms.
As an investigational neuroprotective intranasal drug, ONP-002 targets the biological cascade triggered by trauma, with the potential to represent a paradigm shift from symptom management to active neurological intervention.
ONP-002 is delivered via Oragenics’ proprietary intranasal spray-dry powder device. The drug candidate serves a nasal drug delivery market expected to reach nearly $93 billion by 2030.
